1. Home
  2. ARQT vs GDV Comparison

ARQT vs GDV Comparison

Compare ARQT & GDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
    SELLHOLDBUYas of 20 hours ago
  • GDV
    SELLHOLDBUYas of 20 hours ago
  • Stock Information
  • Founded
  • ARQT 2016
  • GDV 2003
  • Country
  • ARQT United States
  • GDV United States
  • Employees
  • ARQT N/A
  • GDV N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • GDV Investment Managers
  • Sector
  • ARQT Health Care
  • GDV Finance
  • Exchange
  • ARQT Nasdaq
  • GDV Nasdaq
  • Market Cap
  • ARQT 1.6B
  • GDV 2.0B
  • IPO Year
  • ARQT 2020
  • GDV N/A
  • Fundamental
  • Price
  • ARQT $14.53
  • GDV $23.32
  • Analyst Decision
  • ARQT Strong Buy
  • GDV
  • Analyst Count
  • ARQT 6
  • GDV 0
  • Target Price
  • ARQT $18.80
  • GDV N/A
  • AVG Volume (30 Days)
  • ARQT 2.5M
  • GDV 186.0K
  • Earning Date
  • ARQT 05-06-2025
  • GDV 01-01-0001
  • Dividend Yield
  • ARQT N/A
  • GDV 5.81%
  • EPS Growth
  • ARQT N/A
  • GDV N/A
  • EPS
  • ARQT N/A
  • GDV N/A
  • Revenue
  • ARQT $196,542,000.00
  • GDV N/A
  • Revenue This Year
  • ARQT $57.99
  • GDV N/A
  • Revenue Next Year
  • ARQT $41.24
  • GDV N/A
  • P/E Ratio
  • ARQT N/A
  • GDV N/A
  • Revenue Growth
  • ARQT 229.74
  • GDV N/A
  • 52 Week Low
  • ARQT $6.99
  • GDV $18.04
  • 52 Week High
  • ARQT $17.75
  • GDV $23.00
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 51.52
  • GDV 52.58
  • Support Level
  • ARQT $12.51
  • GDV $22.78
  • Resistance Level
  • ARQT $15.02
  • GDV $23.37
  • Average True Range (ATR)
  • ARQT 1.04
  • GDV 0.71
  • MACD
  • ARQT 0.11
  • GDV 0.17
  • Stochastic Oscillator
  • ARQT 80.42
  • GDV 91.71

Stock Price Comparison Chart: ARQT vs GDV

ARQT
GDV
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April024681012141618202224262830ARQT VS GDV

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About GDV Gabelli Dividend & Income Trust of Beneficial Interest

Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use